Clinical Trial Update: Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating empagliflozin, an SGLT2 inhibitor, for sickle cell–related kidney disease in patients with sickle cell anemia and albuminuri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Albuminuria
• Sickle Cell Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria | Phase 2 | Status: NOT_YET_RECRUITING